Ranbaxy Pays Record $500M To End Tainted Drug Claims

Law360, New York (May 13, 2013, 3:40 PM EDT) -- Ranbaxy Laboratories Ltd. will pay $350 million to settle a Maryland whistleblower False Claims Act suit over selling allegedly adulterated drugs to several government health care programs, plus an additional $150 million after pleading guilty to related felony charges, the U.S. Department of Justice announced Monday.

According to the DOJ, Ranbaxy unit Ranbaxy USA Inc. pled guilty to violating the Food, Drug and Cosmetic Act by knowingly distributing adulterated batches of acne drug Sotret, epilepsy and nerve pain drug gabapentin and antibiotic ciprofloxacin, made in its Paonta...
To view the full article, register now.